119 unknown. 119 Phase 3, 30 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 119 | Unknown 119 |
| Phase 2 | 30 | Unknown 30 |
Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma Nelarabine injection - T-lymphoblastic Leukemia, T-lymphoblastic Lymphoma | Phase 3 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 83 | 2024-05-01 | 2024-05-30 |
| Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult DEC3-VEN - Acute Myeloid Leukemia, Adult | Phase 2 / Phase 3 | Unknown | The Second Affiliated Hospital of Kunming Medical University | 40 | 2024-03-01 | 2024-02-29 |
| A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia Liposomal cytarabine-daunorubicin for injection, 7+3 (cytarabine and daunorubicin) - High-risk (Secondary) Acute Myeloid Leukemia | Phase 3 | Unknown | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 120 | 2024-01-01 | 2023-12-28 |
| Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. olverembatinib - Olverembatinib, Chronic Myeloid Leukemia, Chronic Phase | Phase 3 | Unknown | Shenzhen Second People's Hospital | 40 | 2022-07-01 | 2022-07-29 |
| Caudal Block Versus Dorsal Penile Nerve Block Plus Ring Block for Pain Management of Different Surgical Techniques of Circumcision in Infants and Children Caudal block, Dorsal penile nerve block plus ring block, Circumcision with Plastibell - Anesthesia, Anesthesia, Local | Phase 3 | Unknown | King Saud University | 120 | 2022-03-01 | 2022-02-10 |
| VAH Versus VA for Salvage Therapy of R/R-AML VEN combined with azacitidine plus homoharringtonine, VEN combined with azacitidine - Venetoclax Combined With Azacitidine Plus Homoharringtonine, Venetoclax Combined With Azacitidine | Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 162 | 2022-03-01 | 2022-07-14 |
| Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial rhTPO, Decitabine - Acute Myeloid Leukemia | Phase 3 | Unknown | Huihan Wang | 130 | 2022-01-21 | 2022-05-19 |
| Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL Cladribine, Fludarabine - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 32 | 2022-01-01 | 2022-10-13 |
| Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children Cladribine, G-CSF, Cytarabine - Leukemia, Monocytic, Acute, Pediatric AML | Phase 2 / Phase 3 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 43 | 2021-12-01 | 2023-07-27 |
| Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells, Fludarabine-based chemotherapy + CAR-T-CD19 Cells - Diffuse Large B Cell Lymphoma, Burkitt Lymphoma | Phase 3 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 24 | 2021-09-14 | 2023-07-25 |
| Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation Zebutinib&BR or Zebutinib&FCR - Chronic Lymphocytic Leukemia | Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 45 | 2021-09-01 | 2021-07-28 |
| PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML Visilizumab - Immunotherapy, Refractory Leukemia | Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 30 | 2021-05-01 | 2021-12-03 |
| Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS Azacitidine, all trans retinoic acid - AML, MDS | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 180 | 2021-05-01 | 2022-01-03 |
| A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated SKLB1028, Salvage Chemotherapy - Acute Myeloid Leukemia (AML) | Phase 3 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 315 | 2021-03-24 | 2021-11-02 |
| Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML Venetoclax-Decitabine/Azacitidine-Aclarubicin Association, Venetoclax-Decitabine/Azacitidine Association - Acute Myeloid Leukemia | Phase 3 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 170 | 2021-03-01 | 2023-05-30 |
| ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL ICP-022, Chlorambucil, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Unknown | Beijing InnoCare Pharma Tech Co., Ltd. | 218 | 2021-01-08 | 2023-06-05 |
| Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML Azacitidine, Lenalidomide - Acute Myeloid Leukemia in Remission | Phase 3 | Unknown | Ge Zheng | 60 | 2020-09-01 | 2022-03-24 |
| Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL Flumatinib - Acute Lymphocytic Leukemia, Adult B-Cell, BCR-ABL1 Fusion Protein Expression | Phase 3 | Unknown | Zhongda Hospital | 28 | 2020-03-01 | 2022-03-24 |
| CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression CAR-T CD19 - Acute Myeloid Leukemia | Phase 2 / Phase 3 | Unknown | Sheba Medical Center | 10 | 2020-02-18 | 2023-11-28 |
| The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China 6-mercaptopurine, Standard treatment, Individualized treatment - Acute Lymphoblastic Leukemia, Pediatric | Phase 2 / Phase 3 | Unknown | Wei Zhao | 82 | 2020-02-01 | 2020-01-14 |
Showing 20 of 119. Sign in to see all of them.
Leukemia, Myeloid, Acute (51) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (29) · Leukemia, Lymphocytic, Chronic, B-Cell (19) · Lymphoma (12) · Lymphoma, Follicular (12) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (11) · Myelodysplastic Syndromes (11) · Lymphoma, Large B-Cell, Diffuse (10) · Lymphoma, Mantle-Cell (10) · Lymphoma, Non-Hodgkin (10) · Lymphoma, B-Cell, Marginal Zone (9) · Burkitt Lymphoma (8) · Leukemia, Myeloid, Chronic-Phase (8) · Leukemia, Promyelocytic, Acute (8)
Hemic and Lymphatic Diseases (119) · Neoplasms by Histologic Type (119) · Hematologic Diseases (118) · Neoplasms (117) · Leukemia, Myeloid (72) · Immune System Diseases (49) · Immunoproliferative Disorders (49) · Lymphoproliferative Disorders (49) · Lymphatic Diseases (48) · Leukemia, Lymphoid (46) · Pathological Conditions, Signs and Symptoms (40) · Pathologic Processes (39) · Disease Attributes (35) · Chronic Disease (34)
Cytarabine (33) · Idarubicin (17) · Etoposide (16) · Cyclophosphamide (15) · Daunorubicin (14) · Decitabine (13) · Radiotherapy (12) · Methotrexate (11) · Mercaptopurine (9) · Mitoxantrone (9) · Vincristine (9) · Dexamethasone (8) · Peripheral Blood Stem Cell Transplantation (8) · Busulfan (7) · Doxorubicin (7)
European Organisation for Research and Treatment of Cancer - EORTC (10) · The First Affiliated Hospital of Soochow University (9) · Nanfang Hospital, Southern Medical University (8) · Assistance Publique - Hôpitaux de Paris (5) · Medical Research Council (3) · Peking University People's Hospital (3) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (2) · Fujian Medical University (2) · Gilead Sciences (2) · Scotland and Newcastle Lymphoma Group (2) · Seoul St. Mary's Hospital (2) · Sheba Medical Center (2) · Shenzhen Second People's Hospital (2) · St. Anna Kinderkrebsforschung (2) · The Affiliated Hospital of the Chinese Academy of Military Medical Sciences (2)
China (45) · Germany (17) · France (16) · United Kingdom (15) · Italy (13) · Belgium (12) · Netherlands (10) · Austria (9) · Czechia (9) · United States (7) · Croatia (5) · Israel (5) · Poland (5) · Switzerland (5) · Portugal (4)
Xiaowen Tang, Ph.D. (3) · Han Yue, Ph.D (2) · Qifa Liu (2) · Ruediger Hehlmann, MD (2) · Stephen J. Proctor, MD, FRCP, FRCPath (2) · Theo De Witte, MD, PhD (2) · William A. Wegener, MD, PhD (2) · Adriana Balduzzi, MD (1) · Akif Yesilipek, MD Prof (1) · Alan K. Burnett, MD, FRCP (1) · Alexey Maschan (1) · Amir Ali Hamidieh, MD (1) · Annamaria Testi, Dr (1)
PMID 15812540, PMID 21195303, PMID 25753432, PMID 29926156, PMID 30523055, PMID 33242441, PMID 11675328, PMID 12111109, PMID 12153596, PMID 12694250, PMID 12780755, PMID 15010373, PMID 15801953, PMID 15952999, PMID 16155013, PMID 17366834, PMID 18083847, PMID 18182574, PMID 18358930, PMID 19242495, PMID 19826132, PMID 20038732, PMID 20145273, PMID 20407035, PMID 20494931, PMID 20802024, PMID 21106984, PMID 21220611, PMID 21480469, PMID 21846410, PMID 21943236, PMID 22037714, PMID 22074157, PMID 22086414, PMID 22169779, PMID 22265847, PMID 22323480, PMID 22511495, PMID 22847303, PMID 22965967, PMID 23140366, PMID 23244073, PMID 23321258, PMID 23704089, PMID 23841729, PMID 24127444, PMID 24297940, PMID 24344215, PMID 24727815, PMID 24986689
2014 (1)